Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Insulin prices

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research

The companies are working together on cellular medicines to boost, replace or repair biological functions

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

- PMLiVE

Sanofi’s amlitelimab shows positive results in atopic dermatitis

Newly released study data shows consistent reductions in disease severity

- PMLiVE

Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity

Obesity affects approximately 15 million people in the UK

- PMLiVE

Lilly announces acquisition of Ventyx Biosciences for around $1.2bn

Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease

- PMLiVE

Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management

Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg

- PMLiVE

Lilly announces new study data on Inluriyo in metastatic breast cancer

The five-year survival rate for metastatic breast cancer is 30%

- PMLiVE

Lilly and Indiana University collaborate to expand clinical trial access

The five-year agreement includes a focus on R&D for Alzheimer’s disease

- PMLiVE

Lilly announces plans for $6bn US manufacture facility

The site is the third of four new US sites that Lilly has announced

- PMLiVE

Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

While the trials did not meet their primary endpoints, they highlighted important biomarker findings

- PMLiVE

Novo Nordisk reports phase 3 data showing semaglutide reduces liver scarring

Patients with MASH in the ESSENCE phase 3 trial show semaglutide’s potential to improve liver health

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links